Kite begins EU trial of CAR-T therapy – pharmaphorum
pharmaphorum |
Kite begins EU trial of CAR–T therapy
pharmaphorum Axicabtagene ciloleucel is an investigational therapy in which a patient's T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19 – a protein expressed on the cell surface of B-cell lymphomas and leukaemias – and … Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR–T Therapy Candidate for … Prepping for a rapid-fire launch, Kite Pharma gets a pass from FDA on axi-cel panel review Kite Pharma (KITE) Q2 Loss Narrower than Expected, Sales Beat |
